drugset / Trial / NCT01132612

AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis

NCT01132612

Phase 2 Completed 275 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to provide long term clinical data for the compound for the treatment of the indication of moderate to severe chronic plaque-type psoriasis.

Timeline

Start
2010-05-11
Primary completion
2016-10-18
Completion
2016-10-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Secukinumab Monoclonal antibody 150 mg

Indications